Apellis Pharmaceuticals (NASDAQ:APLS) reported quarterly losses of $(0.47) per share which missed the analyst consensus estimate of $(0.38) by 23.36 percent. This is a 62.07 percent decrease over losses of $(0.29) per share from the same period last year. The company reported quarterly sales of $199.913 million which beat the analyst consensus estimate of $199.222 million by 0.35 percent. This is a 5.94 percent decrease over sales of $212.528 million the same period last year.